Galenica


Strong Start to 2025 underpinned by broad-based growth

22/05/25 -"Galenica reported robust growth from January to April 2025, with revenue increasing by 4.7% to CHF 1,314.2 million, outperforming the broader pharmaceutical market. Growth was widespread across ..."

Pages
47
Language
English
Published on
22/05/25
You may also be interested by these reports :
24/05/25
The Q1 25 results of Allegro Group were 3.6-3.8% above the PAP consensus on the EBIT and net income level. The negative aspect was the >85% lower ...

23/05/25
H&M (Reduce; Sweden) continues to face a challenging operating environment in 2025. Following a soft start to the year, back in late March the group ...

22/05/25
Galenica reported robust growth from January to April 2025, with revenue increasing by 4.7% to CHF 1,314.2 million, outperforming the broader ...

22/05/25
We have adopted a more pessimistic view of Travis Perkins’ performance over the near/mid-term. Although we had previously expected the group’s ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO